Endeavour Invest shareholder company, Cell to Cure, has introduced a new corporate visual identity to support its continued development and evolving role within advanced cell-based therapies.
A part of shaping future progress
The updated identity includes a sweeping online and offline visual modernisation, including refreshed company logo and colour palette. The changes are interned to create a clearer and more consistent expression of the company’s scientific work, values and ambitions in their field.
The new identity has been rolled out across all digital and physical touchpoints, reinforcing internal alignment and enhancing external visibility. While not a change in strategy, the visual update signals Cell to Cure’s continued commitment to advancing cell-based therapies and taking new steps in shaping the future of biotech innovation.
About Cell to Cure
Founded in 2018, Cell to Curespecialises in the development and manufacturing of allogenic mesenchymal stomal cell therapies derived from adipose tissue. These therapies are being explored for their potential to threat a range of inflammatory and degenerative diseases, including cardiovascular and autoimmune conditions.
With a strong focus on clinical-grade production and scalability, the company aims to bring safe and effective cell therapies closer to the patients.
